Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 15/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563739 | 0.84 | ADORA2A (0.69) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2563559 | 0.80 | ADORA2A (0.67) | ADORA2AADORA1ADORA2B | |
| SCHEMBL20784751 | 0.75 | ADORA2B (0.64) | ADORA2AADORA2B | |
| SCHEMBL3673822 | 0.74 | ADORA2A (0.62) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6859712 | 0.73 | ADORA2A (0.76) | ADORA2AADORA1ADORA2B | |
| SCHEMBL3671996 | 0.73 | ADORA2A (0.61) | ADORA2AADORA1NAMPT | |
| SCHEMBL3682979 | 0.73 | ADORA2A (0.63) | ADORA2AADORA1NAMPTSMN1; SMN2 | |
| SCHEMBL20784558 | 0.68 | ADORA2B (0.73) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6852772 | 0.66 | ADORA2A (0.74) | ADORA2AADORA1ADORA2B | |
| SCHEMBL4288284 | 0.66 | SOD1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192164-B1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2005-08-17 | — | — | EP | claimed |
| US-6787541-B1 | MOVEMENT DISORDERS, PARKINSON'S DISEASE | VERNALIS RESEARCH LIMITED (GB) | 2004-09-07 | — | — | US | claimed |
| EP-1192164-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-03 | — | — | EP | claimed |
| WO-2001002409-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-01-11 | — | — | WO | claimed |
| WO-2011133696-A2 | METHODS OF SUPPRESSING ATHEROSCLEROSIS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-1192164-B1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-6787541-B1 | MOVEMENT DISORDERS, PARKINSON'S DISEASE | VERNALIS RESEARCH LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1192164-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001002409-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |